Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Remote Ischemic Conditioning for High Altitude Polycythemia in High-Altitude Immigrant Populations

NCT: NCT07562464 · NOT_YET_RECRUITING

NCT IDNCT07562464
StatusNOT_YET_RECRUITING
Start Date2026-05-20
Completion2028-06-30

Brief Summary

This study is a multicenter, prospective, randomized, open-label, parallel-controlled clinical trial. The participants are adult patients with high-altitude polycythemia who have been long-term residents (for \>6 months) in regions at an altitude of ≥2500 meters. Participants are randomly assigned to one of two groups: a conventional medication group and a remote ischemic conditioning (RIC) intervention group. The study aims to evaluate the effectiveness of a standardized 90-day RIC intervention, as an add-on to conventional medication, in managing high-altitude polycythemia.

Frequently Asked Questions

What is Remote Ischemic Conditioning for High Altitude Polycythemia in High-Altitude Immigrant Populations?

Remote Ischemic Conditioning for High Altitude Polycythemia in High-Altitude Immigrant Populations is a clinical trial registered under NCT07562464. Current status: NOT_YET_RECRUITING.

What is the status of NCT07562464?

The current status of NCT07562464 (Remote Ischemic Conditioning for High Altitude Polycythemia in High-Altitude Immigrant Populations) is: NOT_YET_RECRUITING.

When did Remote Ischemic Conditioning for High Altitude Polycythemia in High-Altitude Immigrant Populations start?

Remote Ischemic Conditioning for High Altitude Polycythemia in High-Altitude Immigrant Populations started on 2026-05-20.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.